Expansion opportunities BPS Bioscience has a broad and growing catalog of recombinant enzymes, assay kits, cell lines, CRISPR services, and custom protein expression, suggesting cross-selling potential into adjacent research areas such as immunotherapy, kinases, methyltransferases, and CRISPR-based screening tools.

Collaboration channels Recent partnerships and integrations with Cytion GmbH and TebuBio indicate openness to collaborative product development and co-branded tools, presenting opportunities for joint offerings, co-marketed assays, and bundled testing services.

New assay capabilities Launch of One-Step Luciferase Assay creates a gateway for sales teams to position validated, highly sensitive readouts for mammalian cell culture, appealing to customers needing streamlined assay workflows and scalable screening platforms.

Covid and infectious disease tools Historical focus on Covid-19 tools and pseudoviruses demonstrates established expertise in viral entry biology and neutralization assays, enabling upsell to vaccine developers, antiviral screening programs, and neutralization studies.

Strategic growth timing Revenue range and San Diego location within a dense life sciences cluster, combined with active product expansion and office investment in the past years, signal readiness for enterprise customers seeking reliable, end-to-end drug discovery support and scalable supply.